BTIG raised the firm’s price target on Vaxcyte to $76 from $69 and keeps a Buy rating on the shares after the company announced that it has completed enrollment in its Phase 1/2 clinical study evaluating VAX-31. The analyst is citing the firm’s increased confidence that the XpressCF platform will hold up under the increased load of 31 antigens as it now expects VAX-31 to become the lead PCV at Vaxcyte.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCVX:
- Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
- Vaxcyte appoints Whitney Jones as Chief People Officer
- Vaxcyte Appoints Whitney Jones as Chief People Officer
- Needham ups Phathom target, adds to Conviction List as top 2024 pick
- Vaxcyte gives PCV franchise update, advances adult VAX-31 Phase 1/2 study
